Agent and pharmaceutical composition

Nanoparticles composed of albumin and antioxidants like edaravone target muscle tissue damage in sarcopenia, addressing the lack of therapeutic drugs by delivering effective treatment directly to damaged areas, enhancing muscle recovery and strength.

JP2024162882AInactive Publication Date: 2024-11-21NAT UNIV CORP KUMAMOTO UNIV +1
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2023078846
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Filing Date
2023-05-11
Publication Date
2024-11-21
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

There is a lack of fundamental therapeutic drugs for sarcopenia and nucleic acid medicines for Duchenne muscular dystrophy require frequent medication, posing a heavy burden on patients, with issues such as improving quality of life remaining.

Method used

Development of nanoparticles containing albumin and an active ingredient, which disintegrate in an intracellular reducing environment, targeting muscle tissue damage, particularly in sarcopenic patients, utilizing SPARC protein expression and incorporating antioxidants like edaravone.

Benefits of technology

The nanoparticles effectively deliver antioxidants to damaged muscle tissue, normalizing the intracellular redox balance, suppressing muscle atrophy, and improving muscle strength and mass, providing a novel treatment strategy for sarcopenia.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024162882000001
    Figure 2024162882000001
  • Figure 2024162882000002
    Figure 2024162882000002
  • Figure 2024162882000003
    Figure 2024162882000003
Patent Text Reader

Abstract

To provide an agent and a pharmaceutical composition that are used in treatment of a patient with damaged muscle tissue.SOLUTION: An agent for use in treatment of a patient with damaged muscle tissue contains nanoparticles containing albumin and an active component as an active ingredient.SELECTED DRAWING: None
Need to check novelty before this filing date? Find Prior Art

Description

[Technical field]

[0001] The present invention relates to medicaments and pharmaceutical compositions. [Background technology]

[0002] In Japan, which has entered an ultra-aging society, the number of skeletal muscle-related diseases is increasing. For example, sarcopenia is a disease characterized by skeletal muscle atrophy and muscle weakness, and the number of patients with sarcopenia has been increasing in recent years.

[0003] Muscular dystrophy is a genetic disease whose main pathology is necrosis of muscle fibers. In recent years, there has been active research and development into treatments using nucleic acid drugs (morpholino nucleic acids) for Duchenne muscular dystrophy, and the first therapeutic drug was approved for sale in Japan in 2020 (see, for example, Patent Document 1). [Prior art documents] [Patent documents]

[0004] [Patent Document 1] Patent No. 6141728 Summary of the Invention [Problem to be solved by the invention]

[0005] However, there is still no fundamental treatment for sarcopenia, and groundbreaking treatments for sarcopenia are needed. In addition, nucleic acid drugs for Duchenne muscular dystrophy require weekly drug treatment, which places a heavy burden on patients undergoing this treatment, and there remain issues such as improving QOL. It is therefore an object of the present invention to provide agents and pharmaceutical compositions for use in treating patients suffering from muscle tissue damage. [Means for solving the problem]

[0006] The present invention is as follows. [1] A drug used to treat a patient suffering from muscle tissue damage, the drug comprising nanoparticles as an active ingredient, the nanoparticles including albumin and an active ingredient. [2] The drug described in [1], wherein the nanoparticles are particles that disintegrate in an intracellular reducing environment. [3] The drug according to [1], wherein the nanoparticles contain an intermolecular disulfide conjugate of multiple molecules of albumin and an active ingredient encapsulated within or bound to the conjugate. [4] The drug described in [1], wherein the muscle tissue expresses SPARC protein. [5] The agent described in [1], wherein the active ingredient is an antioxidant. [6] The drug described in [1], wherein the albumin is human serum albumin. [7] The method of claim 1, wherein the patient is a sarcopenia patient. [8] A pharmaceutical composition comprising the agent according to any one of [1] to [7]. Effect of the Invention

[0007] The present invention provides agents and pharmaceutical compositions for use in treating patients suffering from muscle tissue damage. [Brief description of the drawings]

[0008] [Figure 1] This is the synthesis scheme for EeNA (Edaravone-encapsulated Nanospherical Albumin). [Diagram 2] 1 shows an experimental scheme for evaluating vascular permeability using Evans Blue and for evaluating changes in SPARC expression. [Diagram 3] These are the results of vascular permeability evaluation using Evans Blue. [Figure 4] These are the results of evaluating changes in SPARC expression. [Diagram 5] 1 shows an experimental scheme for evaluating the distribution of EeNA in hindlimb-suspended mouse models administered with fluorescently labeled EeNA. Control mice are healthy mice not subjected to hindlimb suspension. [Figure 6]This shows the results of an evaluation of the distribution of EeNA in a hindlimb suspension model mouse administered fluorescently labeled EeNA. [Figure 7] 1 shows an experimental scheme for evaluating the treadmill test and PGC-1α expression in a hindlimb suspension model administered EeNA. Control indicates a healthy mouse that was not subjected to hindlimb suspension. [Figure 8] These are the results of a treadmill test in hindlimb suspension model mice administered EeNA. [Figure 9] These are the results of evaluating the expression of PGC-1α in hindlimb suspension model mice administered EeNA. [Figure 10] 1 shows an experimental scheme for evaluating muscle mass in a hindlimb suspension model administered EeNA. [Figure 11] These are the results of muscle mass evaluation in a hindlimb suspension model administered EeNA. [Figure 12] 1 shows an experimental scheme for evaluating oxidative stress and skeletal muscle damage in a hindlimb suspension model administered EeNA. [Figure 13] These are the results of oxidative stress evaluation in a hindlimb suspension model administered EeNA. [Figure 14] These are the results of evaluating skeletal muscle damage in a hindlimb suspension model administered EeNA. [Figure 15] 1 shows an experimental scheme for evaluating the expression of Myostatin and Atrogin-1 in a hindlimb suspension model administered EeNA. [Figure 16] These are the results of evaluating Myostatin in a hindlimb suspension model administered EeNA. [Figure 17] These are the results of evaluating Atrogin-1 in a hindlimb suspension model administered EeNA. [Figure 18] 1 shows an experimental scheme for evaluating the expression of SPARC and HSA in a hindlimb suspension model administered EeNA. [Figure 19] This shows the results of evaluating the expression of SPARC in a hindlimb suspension model administered EeNA. [Figure 20]This shows the results of evaluating HSA expression in a hindlimb suspension model administered EeNA. [Figure 21] This is an experimental scheme for evaluating the intracellular translocation of EeNA using A549 cells, which highly express SPARC, and HepG2 cells, which have low SPARC expression. [Figure 22] The expression of SPARC in A549 cells and HepG2 cells was evaluated by Western blotting. [Diagram 23] The intracellular translocation of EeNA was evaluated in A549 cells and HepG2 cells using flow cytometry. MFI indicates mean fluorescence intensity. [Figure 24] This shows the results of evaluating SPARC in the culture supernatant of A549 cells and HepG2 cells by Western blotting. [Diagram 25] The intracellular translocation of EeNA in A549 cells and HepG2 cells in the presence or absence of culture supernatant was evaluated using flow cytometry. MFI indicates mean fluorescence intensity. [Figure 26] This is an experimental scheme for evaluating the intracellular translocation of EeNA using A549 cells to which siRNA against SPARC has been added. [Figure 27] 13 shows the results showing SPARC knockdown in A549 cells with the addition of siRNA against SPARC. [Figure 28] The intracellular internalization of EeNA was evaluated by flow cytometry in A549 cells to which siRNA against SPARC had been added. MFI indicates mean fluorescence intensity. [Figure 29] The results are shown in Fig. 1. The intracellular translocation of EeNA in the presence of human serum was evaluated by flow cytometry in A549 cells to which siRNA against SPARC had been added. MFI indicates mean fluorescence intensity. [Diagram 30] This is a summary of the present embodiment. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0009] [Drugs] In one embodiment, the present invention provides a drug for use in treating a patient suffering from muscle tissue damage, the drug comprising as an active ingredient nanoparticles comprising albumin and an active ingredient.

[0010] As described later in the Examples, the inventors have found that albumin has a tropism toward damaged muscle tissue. The drug of this embodiment is used to treat patients with damaged muscle tissue. As patients with damaged muscle tissue, preferred are patients with disrupted vascular structures in muscle tissue, patients with skeletal muscle damage, and patients with extravasation of albumin.

[0011] Furthermore, the muscle tissue preferably expresses a SPARC protein. SPARC (secreted protein acidic and rich in cysteine) protein is a secreted protein that is acidic and rich in cysteine, and is known to be highly expressed in muscle tissues associated with muscle disorders. The amino acid sequence constituting the SPARC protein is represented, for example, by SEQ ID NO: 1. The DNA sequence encoding the SPARC protein is represented, for example, by SEQ ID NO: 2. As described later in the Examples, the inventors have clarified that the SPARC protein is involved in the uptake of the drug of this embodiment. Whether or not muscle tissue expresses the SPARC protein may be confirmed by analyzing the expression level of the SPARC protein, or by analyzing the expression level of SPARC DNA or SPARC mRNA. Since the SPARC protein is a secreted protein, the expression of SPARC can be confirmed using a patient's blood sample.

[0012] The albumin used in the drug of this embodiment is preferably derived from a mammal, preferably from a human, monkey, mouse, rat, etc., and is preferably human serum albumin (HSA).

[0013] The nanoparticles used in the drug of this embodiment contain albumin and an active ingredient. The nanoparticles are preferably particles that disintegrate in an intracellular reducing environment, and more preferably particles that contain an intermolecular disulfide bond between multiple albumin molecules and the active ingredient encapsulated or bonded to the bond. As an example, nanoparticles are produced through the following process: an albumin solution is reduced with reduced glutathione to cleave the intramolecular disulfide bonds of albumin. Next, an active ingredient is mixed into the reduced albumin solution, and then intermolecular disulfide bonds between multiple albumin molecules are formed by desolvation using ethanol or the like. Through these processes, nanoparticles that are intermolecular disulfide bonds between multiple albumin molecules encapsulating an active ingredient are produced. After the nanoparticles are transferred to the damaged muscle tissue, the intermolecular disulfide bonds are cleaved in the intracellular reducing environment, and the particles disintegrate. Upon disintegration, the encapsulated active ingredient is released, providing a medicinal effect to the damaged muscle tissue. The nanoparticles maintain a stable particle structure without the use of crosslinking agents such as glutaraldehyde, and can be used clinically as highly biocompatible carriers. Furthermore, even when the nanoparticles are freeze-dried, there is no significant change in their particle size before and after resuspension, and no aggregates are formed. In other words, the freeze-dried nanoparticles can be stored for a long time and can be easily reconstituted by resuspension in water.

[0014] The particle size of the nanoparticles used in the agent of the present embodiment is not particularly limited, and is preferably 10 to 500 nm, more preferably 20 to 250 nm, even more preferably 30 to 120 nm, and particularly preferably 50 to 100 nm. By adjusting the particle size, it is possible to obtain nanoparticles that can be loaded with a higher concentration of drug, can exist more stably in blood without disintegrating, and can release the loaded drug after being transferred into target cells.

[0015] The active ingredient contained in the nanoparticles is not particularly limited as long as it is an active drug that has a medicinal effect on muscle tissue, and is preferably one that has a high affinity with albumin. Examples of the active ingredient include low molecular weight compounds, nucleic acids, proteins, peptides, etc. Examples of the low molecular weight compounds include those that act on target enzymes or target receptors. Examples of nucleic acids include cDNA, mRNA, siRNA, shRNA, miRNA, and antisense RNA. Examples of proteins include enzymes, antibodies, etc. Examples of peptides include ligands, vaccines, etc. In addition, the active ingredient can also be a genome editing-related factor.For example, in the CRISPR-Cas9 system, a Cas9 expression vector and an expression vector encoding a guide RNA that guides Cas9 to a target gene can be used as active ingredients, and nanoparticles containing this active ingredient can be used for gene therapy.

[0016] An example of an active ingredient is an antioxidant, such as edaravone, allopurinol, ebselen, erdosteine, N-acetylcysteine, silymarin, naringerin, ascorbic acid, cysteine, sodium sulfite, sodium hydrogen sulfite, sodium pyrosulfite, alpha-thioglycerin, citric acid, sodium thioglycolate, sodium edetate, methionine, tocopherol, butylated hydroxyanisole, or dibutylated hydroxytoluene.

[0017] Examples of diseases with muscle tissue damage include diseases related to muscle atrophy and muscle weakness. Muscle atrophy means a decrease in muscle mass, specifically, skeletal muscle atrophy. Examples of symptoms related to muscle atrophy and muscle weakness include disuse muscle atrophy, neurogenic muscle atrophy, and myogenic muscle atrophy. Examples of disuse muscle atrophy include sarcopenia. Examples of neurogenic muscle atrophy include amyotrophic lateral sclerosis, primary lateral sclerosis, spinal muscular atrophy, spinal-bulbar muscular atrophy, acute poliomyelitis, and Guillain-Barre syndrome. Examples of myogenic muscle atrophy include muscular dystrophy and polymyositis.

[0018] Pharmaceutical Composition The present embodiment provides a pharmaceutical composition comprising the above-mentioned drug. The pharmaceutical composition of the present embodiment can be administered orally in the form of, for example, tablets, coated tablets, pills, powders, granules, capsules, liquids, suspensions, emulsions, etc., or parenterally in the form of injections, suppositories, skin topicals, etc.

[0019] The pharmaceutical composition of the present embodiment may contain a pharma- ceutically acceptable carrier. As the pharma- ceutically acceptable carrier, those used in ordinary preparations can be used without any particular limitation. More specifically, for example, binders such as gelatin, corn starch, tragacanth gum, gum arabic, etc.; excipients such as starch and crystalline cellulose; swelling agents such as alginic acid; solvents for injections such as water, ethanol, and glycerin; adhesives such as rubber-based adhesives and silicone-based adhesives, etc. The pharma- ceutical acceptable carriers can be used alone or in combination of two or more.

[0020] The pharmaceutical composition of the present embodiment may further contain additives, such as lubricants such as calcium stearate and magnesium stearate, sweeteners such as sucrose, lactose, saccharin and maltitol, flavorings such as peppermint and saffron oil, stabilizers such as benzyl alcohol and phenol, buffers such as phosphates and sodium acetate, solubilizers such as benzyl benzoate and benzyl alcohol, antioxidants, and preservatives. The additives may be used alone or in combination of two or more.

[0021] (Administration Method) The method of administration of the pharmaceutical composition of this embodiment is not particularly limited, and may be appropriately determined depending on the symptoms, body weight, age, sex, etc. of the patient. For example, tablets, coated tablets, pills, powders, granules, capsules, liquids, suspensions, emulsions, etc. are orally administered. Injections are administered intravenously alone or in combination with a normal replacement fluid such as glucose or amino acids, and further administered intraarterially, intramuscularly, intradermally, subcutaneously, or intraperitoneally as necessary.

[0022] (Dosage) The dosage of the pharmaceutical composition of the present embodiment varies depending on the symptoms, body weight, age, sex, etc. of the patient and cannot be determined in general, but in the case of oral administration, for example, 1 μg to 10 g, for example, 0.01 to 2000 mg of the active ingredient may be administered per day. In the case of injection, for example, 0.1 μg to 1 g, for example, 0.001 to 200 mg of the active ingredient may be administered per day. In the case of suppository, for example, 1 μg to 10 g, for example, 0.01 to 2000 mg of the active ingredient may be administered per day.

[0023] [Treatment method] The present embodiment provides a method for treating a patient suffering from muscle tissue damage, comprising administering the above-described pharmaceutical composition to a patient in need of treatment.

[0024] [Other embodiments] The present embodiment provides a use of the pharmaceutical composition for manufacturing a therapeutic agent for a patient suffering from muscle tissue damage. The pharmaceutical composition may be the same as that described above.

[0025] <Companion diagnostics> This embodiment provides a companion diagnostic agent for use in treating patients with damaged muscle tissue using the above-mentioned pharmaceutical composition, the diagnostic agent comprising an anti-SPARC protein antibody, or a primer set for amplifying the SPARC gene, and / or a probe that binds to the SPARC gene or its amplification product.

[0026] Since the SPARC protein is a secreted protein, the expression of SPARC can be confirmed using a blood sample from a patient, and therefore, it is preferable to use the expression level of the SPARC gene or the SPARC protein as an index for identifying a patient for whom the pharmaceutical composition of the present embodiment is to be used.

[0027] Furthermore, in addition to the above-mentioned antibody, primer set, and / or probe, the kit may include an ELISA kit for detecting SPARC protein, a kit for extracting nucleic acid (e.g., total RNA) from body fluids, cells, tissues, etc., fluorescent substances for labeling, reagents for amplifying nucleic acid, etc. Examples of samples include blood, urine, saliva, sweat, tissue exudate, etc., with blood being preferred. Methods for detecting SPARC in a patient-derived sample may include analyzing the expression level of SPARC protein using ELISA or the like, amplifying a SPARC DNA fragment by PCR using primers and analyzing the amplified product, or analyzing by a method using hybridization using a probe complementary to a specific SPARC DNA or SPARC mRNA. EXAMPLES

[0028] The present invention will be described in more detail below with reference to experimental examples, but the present invention is not limited to these examples.

[0029] Sarcopenia is defined as a disease that shows a decrease in muscle mass due to aging, bedriddenness, etc. It is known that sarcopenia is induced by disuse muscle atrophy due to muscle inactivity, nutritional deficiencies, aging, and other diseases. Current treatments for sarcopenia are limited to symptomatic treatments such as exercise therapy and nutritional therapy. However, exercise therapy in particular is often difficult for patients who have experienced disuse muscular atrophy, and there is a demand for drugs to treat sarcopenia.

[0030] When reactive oxygen species (ROS) are produced by exercise, etc., the expression of PGC-1α, which is involved in mitochondrial biogenesis, is induced. PGC-1α then alleviates oxidative stress caused by ROS through the production of antioxidants, contributing to the maintenance of mitochondrial function and muscle strength and mass.

[0031] On the other hand, in disuse muscle atrophy due to inactivity, as typified by sarcopenia, excessive ROS produced in muscle tissue induces mitochondrial dysfunction, resulting in the production of mtROS, a type of ROS derived from mitochondria. If antioxidants become insufficient due to an increase in this series of ROS, the intracellular redox balance is disrupted, leading to further mitochondrial dysfunction and a sustained decline in muscle strength and mass. For this reason, it is important to remove the excess ROS produced using antioxidants in order to inhibit the progression of the disease.

[0032] In this Example, attention was focused on edaravone, which is reported to have an inhibitory effect on the production of mtROS among antioxidants against oxidative stress.

[0033] Edaravone is an antioxidant that has excellent scavenging ability for various intracellular ROS and has a very high binding rate with human serum albumin. However, since it is distributed throughout the body after administration, accumulation at the site of muscle atrophy is insufficient, and formulation ingenuity is required to control its dynamics. Therefore, focusing on the fact that edaravone has a high affinity for human serum albumin, human serum albumin (HSA) was selected as a carrier. HSA is highly biocompatible and is characterized by being mostly decomposed in muscles, making it an excellent carrier.

[0034] In addition, SPARC, a myokine that is highly expressed in muscle tissue and released into the bloodstream following muscle breakdown, is known to have high affinity for HSA, and thus SPARC may be a driving force for the cellular uptake of HSA, which is used as a carrier. Considering the above-mentioned pharmaceutical properties of edaravone and the pathological characteristics of muscle degradation, HSA nanoparticles encapsulating edaravone were prepared in this example. The prepared nanoparticles may be able to control the pharmacokinetics of edaravone and deliver large amounts of edaravone to the diseased site.

[0035] [Preparation of nanoparticles] The HSA solution was reduced with reduced glutathione, and edaravone was mixed into the reduced HSA solution. After that, by forming intermolecular disulfide bonds through desolvation, HSA nanoparticles carrying approximately 20 molecules of edaravone per HSA molecule (hereafter referred to as EeNA (Edaravone-encapsulated Nanospherical Albumin)) were produced (see Figure 1).

[0036] After the EeNA particles migrate into damaged muscle tissue, the intermolecular disulfide bonds are cleaved in the intracellular reducing environment, causing the particles to disintegrate. Upon disintegration, the encapsulated edaravone is released, and its antioxidant effect normalizes the intracellular redox balance, suppressing the progression of sarcopenia.

[0037] [Evaluation of the usefulness of EeNA in disuse muscle atrophy model mice] A hindlimb suspension model mouse was created by suspending the hindlimb of the mouse, and vascular permeability was evaluated using EvansBlue (see Figure 3) and changes in SPARC expression were evaluated (see Figure 4) at the time points shown in Figure 2. On the 14th day after the start of hindlimb suspension, the albumin-binding dye EvansBlue accumulated in the muscle atrophy hindlimb (see Figure 3), suggesting that vascular permeability to albumin had increased. SPARC expression also gradually increased after the start of hindlimb suspension (see Figure 4). These results suggest that HSA has a tropism toward damaged muscle tissue.

[0038] Therefore, EeNA, a nanoparticle composed of HSA, was labeled with the fluorescent dye Cy5 and administered to a hindlimb suspension model mouse. Six hours after administration, the distribution of EeNA was evaluated by ex vivo imaging in the front legs, where muscle atrophy had not occurred, and in the hind legs, where muscle atrophy had occurred (see Figure 5). As a result, fluorescence derived from Cy5 was observed only in the hind legs, where muscle atrophy had occurred, indicating that EeNA can be delivered to damaged muscle tissue (see Figure 6).

[0039] In addition, in Figure 6, SPARC, shown as green fluorescence, was highly expressed in the injured hindlimb muscle tissue and colocalized with the red fluorescence from Cy5-labeled EeNA, suggesting that SPARC may be involved in the intracellular translocation of EeNA.

[0040] [Effectiveness of EeNA on disuse muscle atrophy models] Next, the usefulness of EeNA in a hindlimb suspension model was evaluated. EeNA was administered on days 11 and 13 after the start of hindlimb suspension, and a treadmill running test was performed to evaluate muscle endurance. In addition, the expression of PGC-1α, which is involved in mitochondrial biosynthesis, was evaluated (see Figure 7). As a result, recovery of muscle endurance was observed in the EeNA administration group (see Figure 8), and at the same time, the expression of PGC-1α was also increased (see Figure 9), confirming that EeNA contributes to the suppression of muscle weakness.

[0041] Next, muscle weight was measured to evaluate muscle mass (see Figure 10). As a result, it was confirmed that administration of EeNA inhibited the decrease in muscle weight of the tibialis anterior and gastrocnemius muscles (see Figure 11). Therefore, it was confirmed that EeNA also contributes to inhibiting the decrease in muscle mass associated with hindlimb suspension.

[0042] Furthermore, the amount of malondialdehyde (MDA) in muscle tissue was measured to measure lipid peroxides, which is an indicator of ROS (see Figure 12). As a result, a significant decrease in MDA was observed in the EeNA administration group (see Figure 13). Creatine kinase (CPK), an indicator of skeletal muscle damage, was also measured, and a significant decrease in CPK was observed in the EeNA administration group, just like MDA (see Figure 14).

[0043] Furthermore, when the expression of Myostatin and Atrogin-1, which are involved in muscle protein breakdown, was evaluated by Western blotting (see Figure 15), a significant decrease in Myostatin expression (see Figure 16) and a tendency for Atrogin-1 expression to decrease (see Figure 17) were confirmed in the EeNA-administered group.

[0044] Furthermore, the expression of SPARC and HSA were evaluated by Western blotting (see Figure 18). SPARC expression showed a tendency to decrease with administration of EeNA (see Figure 19), which is considered to be the result of muscle damage being suppressed by the therapeutic effect of EeNA. Furthermore, bands derived from HSA were confirmed only in the group administered EeNA containing HSA (see Figure 20), confirming that EeNA was successfully delivered to muscle tissue.

[0045] [Elucidation of the mechanism of intracellular uptake of EeNA] SPARC, which is known to be highly expressed in muscle tissue following muscle injury, is known to have a high affinity for HSA. As mentioned above, the results of fluorescent immunostaining in Figure 6 confirm the colocalization of EeNA, a nanoparticle composed of HSA, and SPARC.

[0046] It has also been reported that SPARC is important for the uptake of HSA and HSA nanoparticles into tumors, and HSA and HSA nanoparticles bind to SPARC with high affinity and are transported into cancer cells.

[0047] Therefore, it was hypothesized that the transfer of EeNA, a nanoparticle composed of HSA, into muscle cells would occur in a similar manner to the transfer into cancer cells, where EeNA would bind with high affinity to SPARC, the expression of which increases with muscle disorder, and then be taken up.

[0048] Therefore, we evaluated the intracellular translocation of EeNA using A549 cells, which highly express SPARC, and HepG2 cells, which have low SPARC expression (see Figure 21). We added Cy5-labeled EeNA to both cells and evaluated the intracellular uptake by flow cytometry. We confirmed that A549 cells, which highly express SPARC (see Figure 22), significantly uptakes EeNA compared to HepG2 cells, which have low SPARC expression (see Figure 23).

[0049] In addition, because SPARC is a secreted hormone, when SPARC in the culture supernatant was evaluated by Western blotting, high expression was also observed in the supernatant of A549 cells, a SPARC-high expression cell line (see Figure 24). To evaluate the involvement of SPARC contained in the supernatant in the uptake of cells, the culture supernatant of each cell was collected in advance and EeNA was administered after adding the supernatant (supernatant (+) group) or adding D-PBS instead of the supernatant (supernatant (-) group). As a result, significant uptake of EeNA was observed in the supernatant (+) group, in which SPARC was contained in the supernatant (see Figure 25). It was therefore confirmed that both SPARC expressed in the cells and secreted SPARC are involved in the uptake of EeNA.

[0050] Therefore, we used siRNA to suppress the expression of SPARC in A549 cells and performed a similar evaluation (see Figure 26). As a result, knocking down SPARC in the cells (see Figure 27) suppressed the uptake of EeNA (see Figure 28). In addition, human serum was added as a competitive experiment to evaluate whether HSA in the serum affects the intracellular uptake of EeNA. As a result, the existence of an intracellular uptake pathway of EeNA other than SPARC was revealed. Next, when the columns of the si control group and the si SPARC group were compared, the difference between the columns indicates the uptake of EeNA mediated by SPARC in the presence of human serum, i.e., in a physiological environment (see Figure 29). Thus, a series of studies using SPARC silencing revealed that SPARC is involved in the intracellular uptake of EeNA.

[0051] As described above, in healthy mice, there is no disruption of the vascular structure in muscle tissue, so there is no extravasation of albumin, and there is also little expression of SPARC, so it was confirmed that EeNA does not migrate to muscle tissue. On the other hand, when there is disruption of the vascular structure, as in the hindlimb suspension model, it was confirmed that EeNA permeates the blood vessels, and intracellular migration is promoted by SPARC, whose expression is increased by muscle tissue damage (see Figure 30).

[0052] During muscle atrophy, myostatin and atrogin-1 promote muscle mass loss accompanied by protein degradation, and excessive ROS produced causes mitochondrial dysfunction and muscle strength loss. Once taken up into cells, EeNA breaks down its structure in the intracellular reducing environment and releases the encapsulated edaravone. It has been confirmed that edaravone normalizes the intracellular redox balance by removing intracellular ROS and mtROS, thereby suppressing the progression of muscle atrophy. Thus, EeNA is expected to function as a novel antioxidant treatment strategy for sarcopenia. [Industrial Applicability]

[0053] According to the present embodiment, a drug and a pharmaceutical composition for use in treating a patient suffering from muscle tissue damage can be provided.

Claims

1. 1. A drug for use in treating a patient suffering from muscle tissue damage, comprising: A drug comprising, as an active ingredient, nanoparticles containing albumin and an active ingredient.

2. The drug of claim 1 , wherein the nanoparticle is a particle that disintegrates in an intracellular reducing environment.

3. The method of claim 1 , wherein the nanoparticles comprise an intermolecular disulfide conjugate of multiple molecules of albumin and an active ingredient encapsulated or bound to the conjugate.

4. The method of claim 1 , wherein the muscle tissue expresses a SPARC protein.

5. The method of claim 1, wherein the active ingredient is an antioxidant.

6. The method of claim 1, wherein the albumin is human serum albumin.

7. The drug described in claim 1, wherein the patient is a sarcopenia patient.

8. A pharmaceutical composition comprising an agent according to any one of claims 1 to 7.

Citation Information

Patent Citations

  • Recovering method of palladium by solvent extraction using 1,2-bis(alkyl thio) ethane or the like as extracting agent

    JP1986041728A